Funding Opportunities

Title Announcement Number Activity Code Clinical Trials Status Expiration Date Program Official
Assay Validation of High Quality Markers for Clinical Studies in Cancer PAR-20-313 (UH2/UH3 Clinical Trial Not Allowed) UH2, UH3 Clinical Trial Not Allowed 10/11/2023 Lynn Sorbara, Ph.D.
Assay Validation of High Quality Markers for Clinical Studies in Cancer PAR-20-314 (UH3 Clinical Trials Not Allowed) UH3 10/11/2023 Lynn Sorbara, Ph.D.
Cancer Prevention, Detection, Diagnosis, and Treatment Technologies for Global Health RFA-CA-24-005 (U01 Clinical Trial Optional) U01 Clinical Trial Optional 10/14/2023 Vikrant Sahasrabuddhe, M.B.B.S., M.P.H., Dr.P.H.
Notice of Special Interest (NOSI): Leveraging Real-World Imaging Data for Artificial Intelligence-based Modeling and Early Detection of Abdominal Cancers NOT-CA-21-028 01/08/2024 Natalie Abrams, Ph.D.
Pancreatic Cancer Detection Consortium: Research Units PAR-21-334 (U01 Clinical Trial Optional) U01 Clinical Trial Optional 06/12/2024
Notice of Intent to Publish a Funding Opportunity Announcement for Pre-Cancer Atlas (PCA) Research Centers NOT-CA-23-085 (U01 Clinical Trial Not Allowed) U01 Clinical Trial Not Allowed 09/01/2024 Indu Kohaar, Ph.D.
Notice of Special Interest: Administrative Supplements for Validation Studies of Analytical Methods for Dietary Supplement Constituents (Admin Supp - Clinical Trial Not Allowed) NOT-OD-22-202 Clinical Trial Not Allowed 04/16/2025 Nancy J. Emenaker, Ph.D., R.D.N., L.D., F.A.N.D.
Cancer Tissue Engineering Collaborative: Enabling Biomimetic Tissue-Engineered Technologies for Cancer Research PAR-22-099 (R01 Clinical Trial Optional) R01 Clinical Trial Optional 05/08/2025 Richard Mazurchuk, Ph.D.
Notice of Special Interest (NOSI): Utilization of Cohorts and Prospective Study Designs for Liquid Biopsy Assay Validation for Early Detection of Cancers NOT-CA-23-004 07/02/2025 Matthew Young, Ph.D.
Imaging, Biomarkers and Digital Pathomics for the Early Detection of Premetastatic Cancer and Precancerous Lesions Associated with Lethal Phenotypes PAR-22-131 (R01 Clinical Trial Optional) R01 Clinical Trial Optional 09/08/2025 Richard Mazurchuk, Ph.D.